Simvastatin: a review

@article{Pedersen2004SimvastatinAR,
  title={Simvastatin: a review},
  author={T. Pedersen and J. Tobert},
  journal={Expert Opinion on Pharmacotherapy},
  year={2004},
  volume={5},
  pages={2583 - 2596}
}
Simvastatin is a long-established hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, first introduced in 1988. At the maximal recommended dose of 80 mg/day, it produces an average reduction in low-density lipoprotein cholesterol (LDL-C) of 47%, accompanied by reductions in very LDL-C, triglycerides and apolipoprotein B, and a modest increase in high-density lipoprotein cholesterol. The only important, although rare, adverse effect of simvastatin is myopathy, an effect shared by… Expand
Simvastatin: two decades in a circle.
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Ezetimibe/simvastatin
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Risk for myopathy with statin therapy in high-risk patients.
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
...
1
2
3
4
5
...